aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry
aTyr Pharma published data in the Journal of Biological Chemistry demonstrating anti-fibrotic effects of ATYR0101, a DARS-derived fusion protein that targets LTBP-1 to induce myofibroblast apoptosis. In an in vivo bleomycin lung fibrosis model, ATYR0101 significantly reduced collagen content and Ashcroft score, outperforming the marketed anti-fibrotic nintedanib used as a control.
Key figures
- Drug Name
- ATYR0101
- Phase Of Trial
- IND-enabling (preclinical)
- Expected clinic entry
- 2027
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.